PW Medtech Group Limited provided consolidated earnings guidance for the six months ended June 30, 2022. The Group is expected to record a significant decrease in its profit for the six months ended June 30, 2022, comparing to the profit for the corresponding period in 2021, as the one-off gain of approximately RMB 731.8 million recorded on disposal of the shares of China Biologic Products Holdings in the first half of 2021 (the ``One-off Disposal Gain in 2021'') did not recur in 2022; after excluding the impact of the One-off Disposal Gain in 2021 from the Group's financial results for the six months ended June 30, 2021, the Group is expected to record an increase of at least approximately 80% in its net profit for the six months ended June 30, 2022 as compared to the corresponding period in 2021.